Literature DB >> 11578672

Depression associated with multiple sclerosis. Looking beyond diagnosis to symptom expression.

A Feinstein1, K Feinstein.   

Abstract

BACKGROUND: While it is recognised that patients with multiple sclerosis have a high lifetime risk for major depression, less is known about sub-syndromal presentations of affective instability, i.e., irritability, sadness and tearfulness and how these symptoms of emotional dyscontrol may affect a subject's overall degree of psychological distress.
METHODS: A consecutive sample of 100 out-patients with clinically definite multiple sclerosis attending their yearly neurological examination were assessed for major depression [Structured Clinical Interview for DSM-IV (SCID-1)], pathological laughing and crying [Pathological Laughing and Crying Scale (PLACS)], self report questionnaires documenting mood [Beck Depression Inventory (BDI)] and overall psychological distress [the 28 item General Health Questionnaire (GHQ)].
RESULTS: Seventeen percent of subjects received a diagnosis of major depression, 8% had pathological laughing and crying (PLC), 48% had symptoms of emotional dyscontrol without meeting criteria for a formal psychiatric diagnosis and 27% had minimal psychiatric symptoms (emotionally stable). The groups did not differ with respect to neurological variables. However, on a validated index of psychological distress (i.e., GHQ scores > or =5), there were significantly more subjects with major depression and emotional dyscontrol than those deemed emotionally stable (P<0.0001). LIMITATIONS: The small number of patients with PLC (N=8) curtailed statistical power when it came to analysing this sub-group.
CONCLUSIONS: Clinicians should be sensitive to complaints such as irritability and sadness in patients with multiple sclerosis, even when symptoms do not fulfil criteria for formal, psychiatric diagnoses. Our data demonstrate that such complaints are associated with levels of psychological distress that approach those experienced by patients with major depression. Given that these sub-syndromes of affective instability respond well to pharmacotherapy, detection and treatment can significantly reduce one important aspect of morbidity associated with multiple sclerosis.

Entities:  

Mesh:

Year:  2001        PMID: 11578672     DOI: 10.1016/s0165-0327(00)00298-6

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  20 in total

Review 1.  Neurorehabilitation in multiple sclerosis--what is the evidence-base?

Authors:  Jürg Kesselring
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

2.  Pseudobulbar affect: prevalence and quality of life impact in movement disorders.

Authors:  Roy E Strowd; Michael S Cartwright; Michael S Okun; Ihtsham Haq; Mustafa S Siddiqui
Journal:  J Neurol       Date:  2010-04-08       Impact factor: 4.849

3.  The influences of cytokines as a possible substrate for the psychological effects of immunomodulation therapy in multiple sclerosis.

Authors:  N N Spirin; D S Kasatkin
Journal:  Neurosci Behav Physiol       Date:  2009-01

4.  Association between depression and survival in Chinese amyotrophic lateral sclerosis patients.

Authors:  Qianqian Wei; Zhenzhen Zheng; Xiaoyan Guo; Ruwei Ou; Xueping Chen; Rui Huang; Jing Yang; Huifang Shang
Journal:  Neurol Sci       Date:  2016-01-13       Impact factor: 3.307

5.  Progressive multiple sclerosis and mood disorders.

Authors:  Lorena Lorefice; G Fenu; G Trincas; M F Moro; J Frau; G C Coghe; E Cocco; M G Marrosu; M G Carta
Journal:  Neurol Sci       Date:  2015-04-22       Impact factor: 3.307

Review 6.  Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management.

Authors:  Anja Kurt; Femke Nijboer; Tamara Matuz; Andrea Kübler
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Depression and quality of life in patients with amyotrophic lateral sclerosis.

Authors:  Dorothée Lulé; Sonja Häcker; Albert Ludolph; Niels Birbaumer; Andrea Kübler
Journal:  Dtsch Arztebl Int       Date:  2008-06-06       Impact factor: 5.594

8.  Fatigue and Comorbidities in Multiple Sclerosis.

Authors:  Kirsten M Fiest; John D Fisk; Scott B Patten; Helen Tremlett; Christina Wolfson; Sharon Warren; Kyla A McKay; Lindsay I Berrigan; Ruth Ann Marrie
Journal:  Int J MS Care       Date:  2016 Mar-Apr

9.  Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles.

Authors:  A Riazi; J C Hobart; D L Lamping; R Fitzpatrick; J A Freeman; C Jenkinson; V Peto; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

10.  Health-related quality of life in multiple sclerosis: The impact of disability, gender and employment status.

Authors:  Ariel Miller; Sara Dishon
Journal:  Qual Life Res       Date:  2006-03       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.